跳至主要内容
临床试验/NCT05740644
NCT05740644已完成不适用

Clinical Evaluation of the Zynex Monitoring System, Model CM-1600

Zynex Monitoring Solutions2 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2023年2月13日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
20
试验地点
2
主要终点
CM-1600 Ability to Detect Saline Reinfusion

研究概览

简要总结

This is a prospective, single-arm, non-randomized, non-controlled single-center study for the evaluation of the Zynex CM-1600 in 20 healthy adults undergoing a manual blood loss of up to 500mL followed by an infusion of 1 liter of normal saline.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Participant must have the ability to understand the parameters of participation and provide written informed consent
  • Male or female of any race
  • Participant is adult 18 or older
  • Participant must be willing and able to comply with study procedures and duration
  • In the Principal Investigator's medical judgment, the participant is suitable for a blood draw of up to 500mL
  • Participant must weigh at least 110 pounds

排除标准

  • Any upper extremity amputation
  • Females who are pregnant, who are trying to get pregnant, or have a urine test positive for pregnancy on the day of the study
  • Participant has a heart condition that may interfere with the Zynex CM-1600 (e.g., pacemakers, defibrillator, irregular heartbeat, dextrocardia, etc.)
  • Participant has been diagnosed with chronic fatigue syndrome (also known as chronic fatigue, immune dysfunction syndrome, or myalgic encephalomyelitis)
  • Participant requires equipment and/or devices that may interfere with the Zynex CM-1600 (e.g., life-sustaining equipment, other monitoring devices, insulin pumps, or other implanted devices)
  • Participant is taking coumadin (warfarin), heparin, or other prescription blood thinners for 7 or more days prior to blood draw
  • Participant donated blood within 8 weeks prior to the study blood draw
  • Participant has high or low blood pressure on the day of blood draw (high blood pressure is defined as systolic > 180 mmHg or diastolic > 100 mmHg; low blood pressure is defined as systolic < 100 mmHg or diastolic < 60 mmHg)
  • Participant has symptoms of an active infection or a temperature ≥ 100 °F
  • Female with hemoglobin levels of less than 12.1g/dL or male with hemoglobin levels of less than 13.8g/dL
  • Participants with self-reported heart or cardiovascular conditions such as:
  • History of cardiovascular surgery
  • History of chest pain (angina)
  • Heart rhythms other than a normal sinus rhythm or respiratory sinus arrhythmia
  • History heart attack/myocardial infarction
  • Peripheral arterial disease
  • Carotid artery disease
  • Unexplained shortness of breath
  • Congestive heart failure (CHF)
  • History of stroke/transient ischemic attack
  • Myocardial ischemia
  • Cardiomyopathy
  • Dextrocardia
  • Participants with clotting disorders such as:
  • Hemophilia
  • History of blood clots
  • History of bleeding problems
  • Bruises easily
  • Self-reported health conditions as identified in the Health Assessment Form including:
  • Uncontrolled thyroid disease
  • Kidney disease / chronic renal impairment
  • History of seizures (except childhood febrile seizures)
  • History of unexplained syncope
  • Recent history of frequent migraine headache within the last 2 months
  • Recent head injury within the last 2 months
  • History of cancer, with or without chemotherapy within the last 2 months
  • Other known health conditions deemed unsuitable for participation by the PI when considered upon disclosure on health assessment form

结局指标

主要结局

CM-1600 Ability to Detect Saline Reinfusion

时间窗: Recovery period following saline reinfusion (10 minutes)

The objective of this study is to determine if a saline reinfusion of 1000mL of normal saline can be identified using the non-invasive Zynex CM-1600. This will be measured by determining the percent change in Relative Index (RI) before and after the Saline Reinfusion. The RI is an investigational value which utilizes proprietary algorithms to combine the changes of multiple measured parameters (utilizing a weighted summation of percent change values) which are indicative of relative changes in fluid volume in adult patients into a single value. The RI is a unitless value with no set minimum or maximum, where 100 is a patient's baseline. Based on the nature of the RI itself, a direct interpretation of a positive or negative outcome cannot be derived from the absolute value, instead it could be used to monitor trending of a patient's parameters relative to their baseline.

CM-1600 Ability to Detect Minor Blood Loss

时间窗: Duration of Recovery Period following blood draw (10 minutes)

The objective of this study is to determine if manual blood loss of up to 500mL of blood can be identified using the non-invasive Zynex CM-1600. This will be measured by determining the percent change in Relative Index (RI) before and after the Blood Draw. The RI is an investigational value which utilizes proprietary algorithms to combine the changes of multiple measured parameters (utilizing a weighted summation of percent change values) which are indicative of relative changes in fluid volume in adult patients into a single value. The RI is a unitless value with no set minimum or maximum, where 100 is a patient's baseline. Based on the nature of the RI itself, a direct interpretation of a positive or negative outcome cannot be derived from the absolute value, instead it could be used to monitor trending of a patient's parameters relative to their baseline.

次要结局

未报告次要终点

研究者

发起方
Zynex Monitoring Solutions
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验